目前的药理管理,治疗挑战,以及纤维肌痛综合征的潜在未来治疗选择
Georgina Lum1, Amit Das2, Saad Ahmed3
1Department of Rheumatology, Southend University Hospital, Essex, UK.
Expert opinion on pharmacotherapy
|December 14, 2025
概括
纤维肌痛 (FMS) 是一种复杂的疾病,引起疼痛和疲劳,往往导致残疾. 虽然没有治愈方法,但管理策略可以改善FMS患者的症状和生活质量.
科学领域:
- 类风湿病学 类风湿病学
- 疼痛管理 疼痛管理
- 神经学 神经学
背景情况:
- 纤维肌痛 (FMS) 是一种复杂的疾病,其特点是普遍的疼痛,疲劳和生活质量下降.
- FMS显著影响患者的功能,可能导致残疾并造成经济负担.
- FMS的诊断不足和治疗不足很普遍,特别是在具有同时存在肌肉骨疾病的患者中.
研究的目的:
- 审查纤维肌痛综合征 (FMS) 的当前治疗选择.
- 要突出正在进行的研究FMS的潜在机制.
- 强调FMS诊断和管理策略的重要性.
主要方法:
- 在Cochrane评论和PubMed.com的文献中进行文献搜索.
- 专注于研究研究FMS的治疗方法.
- 对中央敏感化,外围敏感化和炎症功能障碍的研究进行了审查.
主要成果:
- 目前的药理疗法包括普雷加巴林,杜洛西丁和米尔纳西普兰.
- 此外,还在探索非标签疗法和新兴治疗方法,如抗病毒药物和大麻素.
- 由于缺乏特定的生物标志物,客观诊断仍然具有挑战性.
结论:
- 纤维肌痛综合征不是一个排除的诊断.
- 诊断可以验证患者的痛苦和指导管理.
- 虽然没有治愈方法,但有效的管理策略可以改善FMS症状和患者的生活质量.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
Management of Insomnia
495
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
495
Cystic Fibrosis: Management
434
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
434
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Psychosis: Goals of Pharmacotherapy
434
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
434
Analgesia and Pain Management
1.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.4K


